Our clinical development pipeline features three drug candidates, each with distinct, well defined mechanisms of action for attacking cancer. Our pipeline includes two potential best-in-class drug candidates with validated targets – a HDAC inhibitor and a PI3K delta inhibitor – as well as a novel mitochondrial inhibitor with promising anti-cancer activity.

For a closer look at our emerging pipeline of drug candidates, please visit our website at www.meipharma.com/our-programs.

Epignetics Program

Pracinostat HDAC Inhibitor

Learn More

Pracinostat has been designated a Breakthrough Therapy by the FDA in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. Read More

Acute Myeloid Leukemia

Newly diagnosed, ≥75 years or unfit
Phase 3

Myelodysplastic Syndrome

Intermediate-2 & high-risk
Phase 2

Myelofibrosis*

Front Line & Relapsed/Refractory
Investigator Sponsored

Signaling Program

ME-401 PI3K Delta Inhibitor

Learn More

ME-401 is a next-generation oral PI3K delta inhibitor that has the potential for a superior pharmacokinetic profile and an improved therapeutic window compared to other drugs in its class. Read More

B-Cell Malignancies

Recurrent CLL or follicular NHL
Phase 1B

Cancer Metabolism Program

ME-344 Mitochondrial Inhibitor

Learn More

ME-344 displays a novel mechanism of action with evidence of mitochondrial-specific effects in cancer cells, including enhanced anti-tumor activity when combined with a VEGF inhibitor such as Avastin®. Read More

HER2-Negative Breast

Investigator Sponsored